



Progress in Protein Therapeutics

Guest Editor:

Dr. Iman Tavassoly

Independent Researcher, New
York, NY 10029, USA

Deadline for manuscript
submissions:

closed (30 June 2025)

Message from the Guest Editor

In recent years, strides have been made in next-generation monoclonal antibodies, engineering methods for enhanced pharmacokinetics, multifunctional fusion proteins, and innovative delivery methods within the space of protein therapeutics. Ongoing efforts are currently addressing challenges such as immunogenicity, manufacturing complexity, targeting intracellular proteins, and off-target effects to develop more efficacious and precision-medicine-based protein therapeutics.

We are pleased to invite you to contribute original research articles with reference to (but not limited to) new advancements in the design, production, and applications of protein therapeutics and using protein therapeutics for precision medicine practices. We also especially welcome critical review manuscripts with a vision perspective, setting the stage for future research.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
X@Biomed_MDPI